本帖最后由 老马 于 2013-3-13 13:43 编辑 , |- k; ?0 p' H
- e* {6 g7 H0 ^( I' X) Q. j
健择（吉西他滨）+顺铂+阿瓦斯汀
# v7 d: p" I& A Gemzar +Cisplatin + Avastin
3 E8 p) H+ a0 I; q; Jhttp://annonc.oxfordjournals.org/content/21/9/1804.full) y8 V0 u6 d9 v* R& [
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
u2 J! S c: i+ E9 p5 `. |; |Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. + p+ q2 Z! Q2 |! ?
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
" W+ {. J; z1 L
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 617)
" i/ Q% O* Z1 M% O/ X6 c7 T* {+ {5 P/ I
华为网盘附件：) \0 _! }! k# l
【华为网盘】ava.JPG; \& c0 y4 m* b" J L
|
显身卡
